BRCA mutations may improve pembrolizumab response in early TNBC
https://www.facingourrisk.org/XRAY/brca-pembrolizumab-early-triple-negative-breast-cancer
Full article: https://link.springer.com/article/10.1007/s12282-026-01878-9
The BRCAPATH study looked at people with early-stage triple-negative breast cancer (TNBC). Participants received chemotherapy alone or chemotherapy plus the immunotherapy drug Keytruda (pembrolizumab) before surgery. People with a BRCA mutation, particularly those with a BRCA1 mutation, were more likely to have no sign of invasive cancer at the time of surgery than participants without a mutation. The results suggest that among people with early-stage TNBC, those with BRCA mutations are likely to respond well to this treatment.
By: Piri Welcsh, PhD
Reviewed by: Allison Kurian, MD, MSc
Questions To Ask Your Health Care Provider
- How would knowing that I have a mutation in BRCA1 or BRCA2 change my treatment or follow-up care?
- Is Keytruda recommended for me?
-
Are there other treatment options or clinical trials recommended for me?
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.